OVER / UNDER
KXFDAAPPROVE-GED ★ KALSHI ★ MULTI ★ KXFDAAPPROVE-GED ★ KALSHI ★ MULTI ★ KXFDAAPPROVE-GED ★ KALSHI ★ MULTI ★ KXFDAAPPROVE-GED ★ KALSHI ★ MULTI ★ KXFDAAPPROVE-GED ★ KALSHI ★ MULTI ★ KXFDAAPPROVE-GED ★ KALSHI ★ MULTI ★

Will the FDA approve gedatolisib for advanced breast cancer?

Price history — Before Jul 1, 2027

Last 7 days of market YES price (blue) with the fair-price range (orange).

77¢0¢25¢50¢75¢100¢Sat 5/30Sun 5/31Mon 6/1Tue 6/2Wed 6/3TODAY
━ market YES▬ fair range
Market price
Before Jul 1, 2027★ BEST77¢
Before Jan 1, 202768¢
Before Oct 1, 202660¢
Before Aug 1, 202654¢
Before Jul 1, 202617¢
Kalshi • Volume: 5.4K contracts • Updated 4h agoCloses: 2027-07-01
Kalshi · Science and Technology
OU's Pick
YES · Before Jul 1, 2027
at 77¢
Price gap
Kalshi77¢
→
OU's fair90¢
+13¢ underpriced · pays 1.3×
Confidence
Moderate

The FDA granted priority review for gedatolisib with a PDUFA date of July 17 2026 which makes approval before the late 2026 and 2027 dates highly probable.

Wide edge+13¢
Not financial advice. For informational purposes only. Prediction markets involve risk of loss. AI may contain errors.